NEW YORK, April 20, 2018 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group Inc., (Nasdaq:SLS) (SELLAS), a
clinical-stage biopharmaceutical company focused on novel cancer immunotherapies for a broad range of cancer indications, today
announced the appointment of Gene Mack as Chief Financial Officer and Treasurer.
“We are delighted to welcome Gene to our executive team. He has a proven track record of leveraging his deep expertise in
corporate finance and strategy to help companies develop important therapies for patients and deliver significant value for
shareholders,” said Angelos Stergiou, M.D., ScD h.c., President and Chief Executive Officer of SELLAS. “That experience, coupled
with his leadership ability, will be of great value to SELLAS as we continue to advance our pipeline of novel cancer
immunotherapies and expand our management team.”
Mr. Mack joins SELLAS having served as a consulting chief financial officer for a number of private and publicly traded
biotechnology and pharmaceutical companies, developing strategy and leading management of all company finance, accounting, and
treasury functions, most recently with Nicox, SA. Prior to consulting, Mr. Mack held finance and business development positions at
Ascendia Pharmaceuticals and Edge Therapeutics. Over the past 5 years, Mr. Mack has raised over $300 million in equity and debt
financing while also advising on numerous successful M&A and product licensing transactions. Mr. Mack also spent over 13 years
as a senior publishing analyst in life sciences equity research at Brean Capital, Lazard, and HSBC Capital Markets. Mr. Mack began
his career conducting clinical research at Columbia University College of Physicians and Surgeons. Mr. Mack holds a B.S. in
Biochemistry and an M.B.A. in Finance, both from Fordham University.
“With a diverse, late-stage pipeline of immunotherapies, SELLAS has the potential to bring innovative new treatments to patients
with life-threatening diseases,” said Mr. Mack. “I am thrilled to join SELLAS’ experienced leadership team and look forward to
contributing to the company’s growth at this exciting time.”
Interim Chief Financial Officer Aleksey Krylov will remain with SELLAS until July 15th in order to facilitate the
transition. “I would like to thank Aleksey for his service as Interim Chief Financial Officer. He has achieved multiple milestones
for SELLAS, including the completion of our reverse merger and the closing of our recent strategic financing,” said Dr.
Stergiou.
About SELLAS Life Sciences Group
SELLAS is a clinical-stage biopharmaceutical company focused on novel cancer immunotherapeutics for a broad range of cancer
indications. SELLAS’ lead product candidate, galinpepimut-S (GPS), is licensed from Memorial Sloan Kettering Cancer Center and
targets the Wilms Tumor 1 (WT1) protein, which is present in an array of tumor types. GPS has potential as a monotherapy or
in combination to address a broad spectrum of hematologic malignancies and solid tumor indications. SELLAS has Phase 3
clinical trials planned (pending funding availability) for GPS in two indications, acute myeloid leukemia (AML) and malignant
pleural mesothelioma (MPM) and is also developing GPS as a potential treatment for multiple myeloma and ovarian cancer.
SELLAS plans to study GPS in up to four additional indications. SELLAS has received Orphan Drug designations from the U.S.
Food & Drug Administration (FDA), as well as the European Medicines Agency, for GPS in AML and MPM; GPS also received Fast Track
designation for AML and MPM from the FDA.
For more information on SELLAS, please visit www.sellaslifesciences.com.
Investor Contact:
Will O’Connor
Stern Investor Relations, Inc.
212-362-1200
ir@sellaslife.com
David Moser, JD
SELLAS Life Sciences Group, Inc.
813-864-2571
info@sellaslife.com
Source: SELLAS Life Sciences Group, Inc.
